Literature DB >> 27829595

Imiquimod-induced CCR9 Ameliorates murine TNBS Colitis.

Ryoma Suzuki, Kyoko Katakura, Tatsuo Fujiwara, Naohiko Gunji, Hiroshi Watanabe, Hiromasa Ohira.   

Abstract

AIMS: To investigate whether Imiquimod (IMQ) as TLR7 ligand protects mice from colonic inflammation and the mechanisms underlying in such immunoregulatory conditions. 
METHODS: Murine colitis was induced to Balb/c mice by administration of trinitrobenzene sulfonic acid (TNBS) with or without daily intraperitoneal administration of IMQ. Colitis was evaluated by body weight decreases and by histological score. Also colonic mRNA expression was measured by RT-PCR. To confirm the induction of Regulatory T cells (Tregs) by type-1 IFN from pDCs, we generated mouse bone marrow-derived pDCs and co-cultured these with CD4+ T cells isolated from mouse spleen with or without IMQ stimulation. Cytokine production in the culture supernatant was measured by ELISA and the number of Tregs were analyzed by flow cytometry. Spleen and mesenteric lymph nodes (MLN) from IMQ-treated mice were collected, and mRNA expressions of cytokine were measured by RT-PCR and cytokine productions were measured by ELISA. Tregs and chemokine expressions were analyzed in colon of TNBS-induced colitis mouse by immunohistochemistry. 
RESULTS: Administration of IMQ significantly suppressed colonic inflammation of TNBS-induced colitis. In the colons of IMQ-treated mice, mRNA expression of TNF-α was decreased, and strong expressions of IL-6, IFN-β and TGF-β were detected. IL-10 and TGF-β productions were increased in the supernatant of co-cultured cells stimulated with IMQ, although we were unable to detect Treg differentiaton in IMQ-stimulated co-cultured cells. In MLN of IMQ-treated mice, strong expressions of TLR7, IFN-β, TGF-β and Foxp3 mRNA were detected. IL-10 production from MLN cells was also increased in the IMQ-treated group. Finally, Tregs in the inflamed colon and CCR9 in MLN of IMQ-treated mice were detected. 
CONCLUSION: These results suggest that IMQ protects mice from TNBS colitis through induction of CCR9, which regulates accumulation of Tregs in the inflamed colon.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27829595      PMCID: PMC5283948          DOI: 10.5387/fms.2015-28

Source DB:  PubMed          Journal:  Fukushima J Med Sci        ISSN: 0016-2590


  36 in total

Review 1.  IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors.

Authors:  Yong-Jun Liu
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

2.  Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I.

Authors:  Tiziana Di Pucchio; Bithi Chatterjee; Anna Smed-Sörensen; Sandra Clayton; Adam Palazzo; Monica Montes; Yaming Xue; Ira Mellman; Jacques Banchereau; John E Connolly
Journal:  Nat Immunol       Date:  2008-03-30       Impact factor: 25.606

3.  Type I interferons maintain Foxp3 expression and T-regulatory cell functions under inflammatory conditions in mice.

Authors:  Shee Eun Lee; Xiangli Li; Joanna C K Kim; Jongdae Lee; Jose M González-Navajas; Seol Hee Hong; In-Kyu Park; Joon Haeng Rhee; Eyal Raz
Journal:  Gastroenterology       Date:  2012-04-01       Impact factor: 22.682

4.  Toll-like receptor 9-induced type I IFN protects mice from experimental colitis.

Authors:  Kyoko Katakura; Jongdae Lee; Daniel Rachmilewitz; Gloria Li; Lars Eckmann; Eyal Raz
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

5.  Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis.

Authors:  Daniel Rachmilewitz; Fanny Karmeli; Kenji Takabayashi; Tomoko Hayashi; Leonor Leider-Trejo; Jongdae Lee; Lorenzo M Leoni; Eyal Raz
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

Review 6.  Imiquimod applied topically: A novel immune response modifier.

Authors:  S Tyring
Journal:  Skin Therapy Lett       Date:  2001-03

7.  Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells.

Authors:  D C Baumgart; D Metzke; J Schmitz; A Scheffold; A Sturm; B Wiedenmann; A U Dignass
Journal:  Gut       Date:  2005-02       Impact factor: 23.059

8.  Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system.

Authors:  Marco Prinz; Hauke Schmidt; Alexander Mildner; Klaus-Peter Knobeloch; Uwe-Karsten Hanisch; Jenni Raasch; Doron Merkler; Claudia Detje; Ilona Gutcher; Jörg Mages; Roland Lang; Roland Martin; Ralf Gold; Burkhard Becher; Wolfgang Brück; Ulrich Kalinke
Journal:  Immunity       Date:  2008-05       Impact factor: 31.745

9.  CCR9 expression defines tolerogenic plasmacytoid dendritic cells able to suppress acute graft-versus-host disease.

Authors:  Husein Hadeiba; Tohru Sato; Aida Habtezion; Cecilia Oderup; Junliang Pan; Eugene C Butcher
Journal:  Nat Immunol       Date:  2008-10-05       Impact factor: 25.606

10.  Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD)

Authors:  R Duchmann; I Kaiser; E Hermann; W Mayet; K Ewe; K H Meyer zum Büschenfelde
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

View more
  2 in total

1.  Therapeutic effect of imiquimod on dextran sulfate sodium-induced ulcerative colitis in mice.

Authors:  Lu Chen; Zhongyin Zhou; Yan Yang; Na Chen; Hongyu Xiang
Journal:  PLoS One       Date:  2017-10-19       Impact factor: 3.240

Review 2.  Emerging Mechanisms of Innate Immunity and Their Translational Potential in Inflammatory Bowel Disease.

Authors:  Daniele Corridoni; Thomas Chapman; Tim Ambrose; Alison Simmons
Journal:  Front Med (Lausanne)       Date:  2018-02-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.